Myriad Genetics Inc
MYGN· Nasdaq
MYGNMyriad Genetics Inc
Filed Feb 25, 2022 · 10-K · 56 days after period end · 0000899923-22-000033
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $160.80M | $154.60M | $195.10M | $216.80M |
| Net Income | -$7.60M | -$37.90M | -$8.30M | $2.60M |
| EPS Diluted | — | -$0.50 | -$0.11 | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 25, 2022 · 56 d after period end
